Austin

Running trials

• Recruiting

  A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

  NCT07735637· Phase 3· Source

• Recruiting

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· Phase 3· Source

• Recruiting

  A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

  NCT07430306· Phase 3· Source

• Recruiting

  A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  NCT07391657· Phase 3· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

  NCT07276581· Phase 2· Source

• Recruiting

  Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  NCT07291037· Phase 3· Source

• Recruiting

  Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

  NCT07129993· Phase 2/3· Source

• Recruiting

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  NCT06952803· Phase 3· Source

• Recruiting

  Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  NCT07044336· Phase 3· Source

• Recruiting

  Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

  NCT06921785· Phase 3· Source

• Recruiting

  DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  NCT06989112· Phase 3· Source

• Recruiting

  Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

  NCT06932263· Phase 2· Source

• Recruiting

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· Phase 3· Source

• Recruiting

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· Phase 3· Source

• Active, not recruiting

  Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

  NCT06608927· Phase 3· Source

• Recruiting

  Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

  NCT06526793· Phase 2· Source

• Active, not recruiting

  A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

  NCT06564844· Phase 3· Source

• Recruiting

  A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

  NCT06549595· Phase 3· Source

• Recruiting

  Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

  NCT06307665· Phase 3· Source

• Active, not recruiting

  Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

  NCT06422689· Phase 4· Source

• Active, not recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

  NCT06268873· Phase 3· Source

• Recruiting

  A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

  NCT06129864· Phase 3· Source

• Active, not recruiting

  Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

  NCT06087835· Phase 3· Source

• Active, not recruiting

  BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

  NCT05943106· Phase 3· Source

• Recruiting

  AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

  NCT05850234· Phase 1/2· Source

• Active, not recruiting

  Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

  NCT05348577· Phase 3· Source

• Active, not recruiting

  Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

  NCT04960709· Phase 3· Source

• Active, not recruiting

  A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

  NCT04594642· Phase 1· Source

• Active, not recruiting

  A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

  NCT04711252· Phase 3· Source

• Active, not recruiting

  Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

  NCT04494425· Phase 3· Source

• Active, not recruiting

  Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

  NCT03997123· Phase 3· Source

• Active, not recruiting

  Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

  NCT03833154· Phase 3· Source

• Active, not recruiting

  A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

  NCT03800134· Phase 3· Source

• Active, not recruiting

  Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

  NCT02475681· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma3 recruiting
• Asthma2 recruiting
• Endometrial cancer2 recruiting
• Follicular lymphoma2 recruiting
• Prostate cancer2 recruiting
• Chronic kidney disease1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Hodgkin lymphoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lung cancer1 recruiting
• Lupus (SLE)1 recruiting
• Rheumatoid arthritis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

  NCT07400588· Phase 2· Source

• Completed

  Aleniglipron Phase 2 Body Composition Study

  NCT07169942· Phase 2· Source

• Completed

  A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

  NCT06644924· Phase 2· Source

• Completed

  Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity

  NCT06579092· Phase 2· Source

• Completed

  A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

  NCT06595238· Phase 2· Source

• Completed

  A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

  NCT06529419· Phase 2· Source

• Recruiting

  Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

  NCT06467357· Phase 3· Source

• Recruiting

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· Phase 3· Source

• Terminated

  Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD

  NCT06192004· Source

• Completed

  A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

  NCT05809934· Phase 2· Source

• Completed

  A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)

  NCT05755906· Phase 3· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

  NCT05364931· Phase 2· Source

• Completed

  Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124

  NCT05459688· Phase 2· Source

• Completed

  Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

  NCT05251259· Phase 2· Source

• Completed

  A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)

  NCT05202262· Phase 3· Source

• Terminated

  Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

  NCT04847232· Phase 3· Source

• Completed

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

  NCT04609878· Phase 3· Source

• Terminated

  A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

  NCT04109950· Phase 3· Source

• Completed

  Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

  NCT02328014· Phase 1/2· Source